Table 1.
Demographic characteristics per primary vaccination with RTS,S/AS01E or HepB and co-administered vaccines (ATP cohort for immunogenicity – FU2).
| Characteristics | Parameters | Group R1 (N = 131) |
Group R2 (N = 111) |
Group R3 (N = 122) |
Group C1 (N = 127) |
Group C2 (N = 107) |
|---|---|---|---|---|---|---|
| Co-administered vaccines |
RTS,S DTaP/Hib tOPV PHiD-CV |
RTS,S DTaP/Hib tOPV HRV |
RTS,S DTaP/Hib tOPV |
HepB DTaP/Hib tOPV PHiD-CV |
HepB DTaP/Hib tOPV HRV |
|
| Staggered vaccines (2 weeks later) |
HRV |
PHiD-CV |
PHiD-CV HRV |
HRV |
PHiD-CV |
|
| Age at HepB booster vaccination (years) | Mean (SD) | 4.3 (0.0) | 4.3 (0.0) | 4.3 (0.0) | 4.3 (0.0) | 4.3 (0.0) |
| Gender | Male, n (%) | 81 (61.8) | 53 (47.7) | 68 (55.7) | 55 (43.3) | 61 (57.0) |
| |
Female, n (%) |
50 (38.2) |
58 (52.3) |
54 (44.3) |
72 (56.7) |
46 (43.0) |
| |
|
RTS,S (N = 364) |
Control (N = 234) |
|||
| Age at HepB booster vaccination (years) | Mean (SD) | 4.3 (0.0) | 4.3 (0.0) | |||
| Gender | Male, n (%) | 202 (55.5) | 116 (49.6) | |||
| Female, n (%) | 162 (44.5) | 118 (50.4) | ||||
ATP, according-to-protocol; DTaP/Hib, diphtheria-tetanus-acellular pertussis- Haemophilus influenzae type b; FU2, follow-up 2; HepB, hepatitis B vaccine; HRV, human rotavirus vaccine; RTS,S/AS01E, malaria vaccine; SD, standard deviation; N, total number of participants; n (%), number (percentage) of participants in the specified category. PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; tOPV, trivalent oral poliovirus vaccine;
RTS,S, all study groups who received primary vaccination with RTS,S/AS01E; control, all study groups who received primary vaccination with HepB.